English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 13 June 2022, 12:00 HKT/SGT
Share:
    

Source: Malaysian Genomics Resource Centre Berhad
Malaysian Genomics Resource Centre Berhad Gets Affected Issuer Status Uplifted
Bursa Securities waives need for Group to submit regularisation plan

PETALING JAYA, Malaysia, June 13, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that it is uplifted from being classified as an affected listed corporation effective 13 June 2022.

Azri Azerai, Executive Director of Malaysian Genomics

Sasha Nordin, CEO and Dato' Alvin Nesakumar, Executive Director of Malaysian Genomics [L-R]

This followed the decision by Bursa Securities Malaysia Berhad to grant the Group a waiver in submitting a regularisation plan after being classified as an affected listed corporation pursuant to Rule 8.03A of the Listing Requirements. Bursa Securities had made the classification according to Rule 8.03A on 24 December 2019 and Malaysian Genomics had submitted an application seeking approval to exempt the Group from submitting a proposed regularisation plan on 24 March 2022. The waiver was granted on 10 June 2022.

Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "I am extremely thankful to the team for working diligently to get Malaysian Genomics out of the affected issuer classification status and welcome this news from the regulator. Our diversification into biopharmaceutical services, in particular the distribution of immunotherapy and cell therapies, has supported the financial performance of the Group. I believe that we can grow together, as a team."

In a recent announcement on its 3Q 2022 performance, Malaysian Genomics reported a profit before tax (PBT) of RM1.96 million compared with PBT of RM0.2 million in 3Q 2021. Earnings per share (EPS) stood at 1.60 sen for 3Q 2022 compared with EPS of 0.19 sen in the corresponding quarter of the previous financial year.

Mr. Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, "We will continue to seek opportunities through collaborations and partnerships targeting new consumer and market segments, including those beyond Malaysia, as we strive to widen our reach and capitalise on heightened awareness on health issues across the region and farther afield. We look forward to introducing new products and markets in the near future."

Dato' Alvin Nesakumar, Executive Director of MGRC, said, "As we have shared before, we are also moving towards offering our products and services through adopting a business-to-consumer strategy to complement our business-to-business approach because trends are changing and technology enables us to reach out directly to consumers. This new approach will give us better insight into what the market needs."

Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/
Malaysian Genomics Resource Centre Berhad: 0155 / [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK]

Topic: Press release summary
Source: Malaysian Genomics Resource Centre Berhad

Sectors: Daily News, BioTech, Healthcare & Pharm, Local Biz
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Malaysian Genomics Resource Centre Berhad Releated News
Aug 18, 2022 18:00 HKT/SGT
Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU
July 20, 2022 13:30 HKT/SGT
UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide
July 15, 2022 14:10 HKT/SGT
Malaysian Genomics Appoints New Chairman
July 13, 2022 15:00 HKT/SGT
Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia
July 8, 2022 18:00 HKT/SGT
Malaysian Genomics Proposes Private Placement
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575